Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX
Market Cap: 440.4B GBX
Have any thoughts about
Dechra Pharmaceuticals PLC?
Write Note

Net Margin
Dechra Pharmaceuticals PLC

-3.7%
Current
6%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3.7%
=
Net Income
-27.9m
/
Revenue
761.5m

Net Margin Across Competitors

Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.1B USD
Net Margin
20%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 348B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.1B USD
Net Margin
7%
Country IE
Market Cap 147.1B USD
Net Margin
-126%
No Stocks Found

Dechra Pharmaceuticals PLC
Glance View

Market Cap
440.4B GBX
Industry
Pharmaceuticals

Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.

DPH Intrinsic Value
58.36 GBX
Overvaluation 98%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3.7%
=
Net Income
-27.9m
/
Revenue
761.5m
What is the Net Margin of Dechra Pharmaceuticals PLC?

Based on Dechra Pharmaceuticals PLC's most recent financial statements, the company has Net Margin of -3.7%.